republic-os/legislation/us/states/il/102nd/hb-1780.md

type, title, description, jurisdiction, legislature, session, identifier, citation, classification, subjects, status, primary_sponsors, version_count, action_count, vote_count, first_action, last_action, source, source_identifier, source_url, source_hash, vintage, source_snapshot, retrieved_at, confidence, tags

type	title	description	jurisdiction	legislature	session	identifier	citation	classification	subjects	status	primary_sponsors	version_count	action_count	vote_count	first_action	last_action	source	source_identifier	source_url	source_hash	vintage	source_snapshot	retrieved_at	confidence	tags
Bill	DRUG TAKE-BACK ACT	Creates the Drug Take-Back Act. Requires covered manufacturers to, no later than July 1, 2022 or 6 months after becoming a covered manufacturer, whichever is later, participate in an approved drug take-back program or have established and implemented a drug take-back program independently or as part of a group of covered manufacturers. Provides requirements for the drug take-back program and for manufacturer program operators. Requires each manufacturer program operator to submit a proposal for the establishment and implementation of a drug take-back program to the Environmental Protection Agency for review and approval. Contains provisions regarding changes or modifications to drug take-back programs, promotion of drug take-back programs, annual reports, funding, and reimbursement. Requires covered manufacturers and manufacturer program operators to submit an annual $5,000 registration fee. Specifies civil penalties for violation of the Act. Preempts home rule powers. Contains other provisions. Amends the Freedom of Information Act. Provides that proprietary information submitted to the Environmental Protection Agency under the Drug Take-Back Act is exempt from inspection and copying under the Act. Effective immediately.	us/states/il	Illinois General Assembly	102nd	HB 1780	Illinois HB 1780 (102nd)	bill		enacted	Jennifer Gong-Gershowitz Laura Fine	8	91	5	2021-02-16	2022-06-10	openstates	ocd-bill/6fdb6974-1464-437b-a80a-8c28f47a03e4	https://ilga.gov/legislation/BillStatus.asp?DocNum=1780&GAID=16&DocTypeID=HB&LegId=130486&SessionID=110&GA=102	241ba6c2704bbd724797e718a2ee5642aecbd113623ebc15d56d328b34851d25	2026-07-01	https://data.openstates.org/daily/2026-07-01/public.pgdump	2026-07-06	reported	legislation bill us-il

Illinois HB 1780 (102nd) — DRUG TAKE-BACK ACT

Creates the Drug Take-Back Act. Requires covered manufacturers to, no later than July 1, 2022 or 6 months after becoming a covered manufacturer, whichever is later, participate in an approved drug take-back program or have established and implemented a drug take-back program independently or as part of a group of covered manufacturers. Provides requirements for the drug take-back program and for manufacturer program operators. Requires each manufacturer program operator to submit a proposal for the establishment and implementation of a drug take-back program to the Environmental Protection Agency for review and approval. Contains provisions regarding changes or modifications to drug take-back programs, promotion of drug take-back programs, annual reports, funding, and reimbursement. Requires covered manufacturers and manufacturer program operators to submit an annual $5,000 registration fee. Specifies civil penalties for violation of the Act. Preempts home rule powers. Contains other provisions. Amends the Freedom of Information Act. Provides that proprietary information submitted to the Environmental Protection Agency under the Drug Take-Back Act is exempt from inspection and copying under the Act. Effective immediately.

Version chain

The bill's text revisions, in order — the diff chain from filing to enrollment.

1. Introduced (filed) — source
2. Engrossed (committee substitute) — source
3. House Amendment 001 (committee substitute) — source
4. House Amendment 002 (committee substitute) — source
5. Senate Amendment 001 (committee substitute) — source
6. Senate Amendment 002 (committee substitute) — source
7. Senate Amendment 003 (committee substitute) — source
8. Enrolled (enrolled) — source

Votes

• Concurrence — 95–14 (pass) · lower
• Third Reading — 96–13 (pass) · lower
• Concurrence — 95–14 (pass) · lower
• Third Reading — 46–2 (pass) · upper
• Concurrence, Amendment 3 — 95–14 (pass) · lower

Sponsors

• Jennifer Gong-Gershowitz — primary (person)
• Laura Fine — primary (person)
• Ann Gillespie — cosponsor (person)
• Ann M. Williams — cosponsor (person)
• Anne Stava-Murray — cosponsor (person)
• Anthony DeLuca — cosponsor (person)
• Antonio Muñoz — cosponsor (person)
• Dagmara Avelar — cosponsor (person)
• Deb Conroy — cosponsor (person)
• Jacqueline Y. Collins — cosponsor (person)
• Jaime M. Andrade, Jr. — cosponsor (person)
• Joyce Mason — cosponsor (person)
• Kambium Buckner — cosponsor (person)
• Kelly M. Cassidy — cosponsor (person)
• Laura Ellman — cosponsor (person)
• Lawrence Walsh, Jr. — cosponsor (person)
• Mark Luft — cosponsor (person)
• Martin McLaughlin — cosponsor (person)
• Michelle Mussman — cosponsor (person)
• Patricia Van Pelt — cosponsor (person)
• Robert Rita — cosponsor (person)
• Robyn Gabel — cosponsor (person)
• Ryan Spain — cosponsor (person)
• Sara Feigenholtz — cosponsor (person)
• Terra Costa Howard — cosponsor (person)
• Tom Demmer — cosponsor (person)

Timeline

The legislative action history — every referral, reading, and vote.

• 2021-02-16 Filed with the Clerk by Rep. Jennifer Gong-Gershowitz filing
• 2021-02-17 First Reading reading-1
• 2021-02-17 Referred to Rules Committee referral-committee
• 2021-02-24 Added Co-Sponsor Rep. Terra Costa Howard
• 2021-02-26 Added Co-Sponsor Rep. Anne Stava-Murray
• 2021-03-01 Added Co-Sponsor Rep. Kelly M. Cassidy
• 2021-03-09 Added Co-Sponsor Rep. Deb Conroy
• 2021-03-09 Assigned to Prescription Drug Affordability & Accessibility Committee referral-committee
• 2021-03-11 Added Co-Sponsor Rep. Kambium Buckner
• 2021-03-26 Added Chief Co-Sponsor Rep. Dagmara Avelar
• 2021-03-26 Added Co-Sponsor Rep. Michelle Mussman
• 2021-03-27 Rule 19(a) / Re-referred to Rules Committee referral-committee
• 2022-01-11 Assigned to Prescription Drug Affordability & Accessibility Committee referral-committee
• 2022-01-26 Added Chief Co-Sponsor Rep. Tom Demmer
• 2022-01-27 Added Co-Sponsor Rep. Robert Rita
• 2022-01-31 House Committee Amendment No. 1 Filed with Clerk by Rep. Jennifer Gong-Gershowitz amendment-introduction
• 2022-01-31 House Committee Amendment No. 1 Referred to Rules Committee referral-committee
• 2022-02-01 Added Co-Sponsor Rep. Ryan Spain
• 2022-02-02 Added Co-Sponsor Rep. Robyn Gabel
• 2022-02-03 Added Co-Sponsor Rep. Ann M. Williams
• 2022-02-07 Added Co-Sponsor Rep. Lawrence Walsh, Jr.
• 2022-02-07 Added Co-Sponsor Rep. Anthony DeLuca
• 2022-02-08 House Committee Amendment No. 1 Rules Refers to Prescription Drug Affordability & Accessibility Committee
• 2022-02-09 House Committee Amendment No. 1 Adopted in Prescription Drug Affordability & Accessibility Committee; by Voice Vote amendment-passage
• 2022-02-09 Do Pass as Amended / Short Debate Prescription Drug Affordability & Accessibility Committee; 015-002-000 committee-passage
• 2022-02-09 Added Co-Sponsor Rep. Martin McLaughlin
• 2022-02-10 Added Co-Sponsor Rep. Joyce Mason
• 2022-02-10 Added Co-Sponsor Rep. Mark Luft
• 2022-02-15 Placed on Calendar 2nd Reading - Short Debate
• 2022-02-15 Added Co-Sponsor Rep. Jaime M. Andrade, Jr.
• 2022-02-16 House Floor Amendment No. 2 Filed with Clerk by Rep. Jennifer Gong-Gershowitz amendment-introduction
• 2022-02-16 House Floor Amendment No. 2 Referred to Rules Committee referral-committee
• 2022-02-17 House Floor Amendment No. 2 Recommends Be Adopted Rules Committee; 004-000-000 committee-passage-favorable
• 2022-02-22 Second Reading - Short Debate reading-2
• 2022-02-22 House Floor Amendment No. 2 Adopted amendment-passage
• 2022-02-22 Placed on Calendar Order of 3rd Reading - Short Debate
• 2022-02-23 Third Reading - Short Debate - Passed 096-013-000 passage, reading-3
• 2022-02-23 Arrive in Senate introduction
• 2022-02-23 Placed on Calendar Order of First Reading reading-1
• 2022-02-23 Chief Senate Sponsor Sen. Laura Fine
• 2022-02-23 Added as Alternate Chief Co-Sponsor Sen. Antonio Muñoz
• 2022-02-23 First Reading reading-1
• 2022-02-23 Referred to Assignments referral-committee
• 2022-03-02 Assigned to Executive referral-committee
• 2022-03-16 Senate Committee Amendment No. 1 Filed with Secretary by Sen. Laura Fine amendment-introduction
• 2022-03-16 Senate Committee Amendment No. 1 Referred to Assignments referral-committee
• 2022-03-18 Senate Committee Amendment No. 2 Filed with Secretary by Sen. Laura Fine amendment-introduction
• 2022-03-18 Senate Committee Amendment No. 2 Referred to Assignments referral-committee
• 2022-03-22 Senate Committee Amendment No. 1 Assignments Refers to Executive
• 2022-03-22 Senate Committee Amendment No. 2 Assignments Refers to Executive
• 2022-03-23 Senate Committee Amendment No. 1 Adopted amendment-passage
• 2022-03-23 Senate Committee Amendment No. 2 Adopted amendment-passage
• 2022-03-23 Do Pass as Amended Executive; 016-000-000 committee-passage
• 2022-03-23 Placed on Calendar Order of 2nd Reading
• 2022-03-23 Second Reading reading-2
• 2022-03-23 Placed on Calendar Order of 3rd Reading March 24, 2022
• 2022-03-25 Senate Floor Amendment No. 3 Filed with Secretary by Sen. Laura Fine amendment-introduction
• 2022-03-25 Senate Floor Amendment No. 3 Referred to Assignments referral-committee
• 2022-03-28 Senate Floor Amendment No. 3 Assignments Refers to Executive
• 2022-03-30 Senate Floor Amendment No. 3 Recommend Do Adopt Executive; 015-000-000
• 2022-03-31 Added as Alternate Co-Sponsor Sen. Ann Gillespie
• 2022-03-31 Added as Alternate Chief Co-Sponsor Sen. Sara Feigenholtz
• 2022-03-31 Added as Alternate Chief Co-Sponsor Sen. Patricia Van Pelt
• 2022-03-31 Added as Alternate Co-Sponsor Sen. Laura Ellman
• 2022-03-31 Recalled to Second Reading reading-2
• 2022-03-31 Senate Floor Amendment No. 3 Adopted; Fine amendment-passage
• 2022-03-31 Placed on Calendar Order of 3rd Reading
• 2022-03-31 Third Reading - Passed; 046-002-000 passage, reading-3
• 2022-03-31 Arrived in House introduction
• 2022-03-31 Placed on Calendar Order of Concurrence Senate Amendment(s) 1, 2, 3
• 2022-04-01 Senate Committee Amendment No. 1 Motion Filed Concur Rep. Jennifer Gong-Gershowitz
• 2022-04-01 Senate Committee Amendment No. 2 Motion Filed Concur Rep. Jennifer Gong-Gershowitz
• 2022-04-01 Senate Floor Amendment No. 3 Motion Filed Concur Rep. Jennifer Gong-Gershowitz
• 2022-04-01 Senate Committee Amendment No. 1 Motion to Concur Referred to Rules Committee referral-committee
• 2022-04-01 Senate Committee Amendment No. 2 Motion to Concur Referred to Rules Committee referral-committee
• 2022-04-01 Senate Floor Amendment No. 3 Motion to Concur Referred to Rules Committee referral-committee
• 2022-04-06 Senate Committee Amendment No. 1 Motion to Concur Recommends Be Adopted Rules Committee; 003-001-000
• 2022-04-06 Senate Committee Amendment No. 2 Motion to Concur Recommends Be Adopted Rules Committee; 003-001-000
• 2022-04-06 Senate Floor Amendment No. 3 Motion to Concur Recommends Be Adopted Rules Committee; 003-001-000
• 2022-04-07 Senate Committee Amendment No. 1 House Concurs 095-014-000
• 2022-04-07 Senate Committee Amendment No. 2 House Concurs 095-014-000
• 2022-04-07 Senate Floor Amendment No. 3 House Concurs 095-014-000
• 2022-04-07 House Concurs
• 2022-04-07 Motion Filed to Reconsider Vote Rep. Daniel Didech
• 2022-04-13 Motion to Reconsider Vote - Withdrawn Rep. Daniel Didech
• 2022-04-13 Passed Both Houses
• 2022-04-22 Added as Alternate Co-Sponsor Sen. Jacqueline Y. Collins
• 2022-05-12 Sent to the Governor executive-receipt
• 2022-06-10 Governor Approved executive-signature
• 2022-06-10 Effective Date June 10, 2022
• 2022-06-10 Public Act . . . . . . . . . 102-1055 became-law

Source

OpenStates / OpenCivicData bulk snapshot 2026-07-01; origin ocd-bill/6fdb6974-1464-437b-a80a-8c28f47a03e4. Confidence: reported (aggregated from official Illinois legislature records).